Anemia of chronic kidney disease

Congestive heart failure

Erythema multiforme

Myocardial infarction

Stevens-Johnson syndrome

Toxic epidermal necrolysis

Pharyngitis

Pure red cell aplasia

Arteriovenous fistula thrombosis

Thrombosis

Stroke

Hypertensive encephalopathy

Urinary tract infections

Bronchitis

Drug hypersensitivity reaction

Hypertensive crisis

Seizures

50-100 unit(s)/kg IV 3× per week

0.45 mcg/kg IV q4 weeks

0.45-0.75 mcg/kg SC weekly

50-100 unit(s)/kg SC 3× per week

0.6 mcg/kg SC q2 weeks

0.6 mcg/kg IV q2 weeks

Methoxy polyethylene glycol-epoetin beta

Epoetin alfa

Darbepoetin alfa

seizure

allergic reactions

bronchospasm

generalized pruritus

skin rash

urticaria

skin blisters

hypotension

diarrhea

vomiting

constipation

headache

muscle spasms

acute back pain

leg pain

arm pain

fluid accumulation

cough

hypertension

↑ serum potassium

hypervolemia

abdominal pain

gastrointestinal bleeding

↓ platelet count

anaphylaxis

angioedema

tachycardia

back pain

limb pain

fever

Treatment of anemia of chronic kidney disease in adults

Treatment of anemia of chronic kidney disease in both children

Methoxy polyethylene glycol-epoetin beta SC

Epoetin alfa SC

Epoetin alfa IV

Darbepoetin alfa IV

Darbepoetin alfa SC

Methoxy polyethylene glycol-epoetin beta IV

Methoxy polyethylene glycol-epoetin beta IV - Congestive HF

Methoxy polyethylene glycol-epoetin beta IV - Hypertension

Methoxy polyethylene glycol-epoetin beta IV - Hypotension

Methoxy polyethylene glycol-epoetin beta IV - Erythema multiforme

Methoxy polyethylene glycol-epoetin beta IV - Myocardial infarction

Methoxy polyethylene glycol-epoetin beta IV - Stevens-Johnson syndrome

Methoxy polyethylene glycol-epoetin beta IV - Toxic epidermal necrolysis

Methoxy polyethylene glycol-epoetin beta IV - Increased serum potassium

Methoxy polyethylene glycol-epoetin beta IV - Hypervolemia

Methoxy polyethylene glycol-epoetin beta IV - Reported abdominal pain

Methoxy polyethylene glycol-epoetin beta IV - Reported constipation

Methoxy polyethylene glycol-epoetin beta IV - Reported diarrhea

Methoxy polyethylene glycol-epoetin beta IV - Gastrointestinal bleeding

Methoxy polyethylene glycol-epoetin beta IV - Pharyngitis

Methoxy polyethylene glycol-epoetin beta IV - Reported vomiting

Methoxy polyethylene glycol-epoetin beta IV - Pure red cell aplasia

Methoxy polyethylene glycol-epoetin beta IV - Arteriovenous fistula thrombosis

Methoxy polyethylene glycol-epoetin beta IV - Thrombosis

Methoxy polyethylene glycol-epoetin beta IV - Decreased platelet count

Methoxy polyethylene glycol-epoetin beta IV - Anaphylaxis

Methoxy polyethylene glycol-epoetin beta IV - Angioedema

Methoxy polyethylene glycol-epoetin beta IV - Bronchospasm

Methoxy polyethylene glycol-epoetin beta IV - Tachycardia

Methoxy polyethylene glycol-epoetin beta IV - Reported skin rash

Methoxy polyethylene glycol-epoetin beta IV - Reported generalized pruritus

Methoxy polyethylene glycol-epoetin beta IV - Reported back pain

Methoxy polyethylene glycol-epoetin beta IV - Urticaria

Methoxy polyethylene glycol-epoetin beta IV - Reported limb pain

Methoxy polyethylene glycol-epoetin beta IV - Stroke

Methoxy polyethylene glycol-epoetin beta IV - Reported muscle spasms

Methoxy polyethylene glycol-epoetin beta IV - Reported headache

Methoxy polyethylene glycol-epoetin beta IV - Hypertensive encephalopathy

Methoxy polyethylene glycol-epoetin beta IV - UTIs

Methoxy polyethylene glycol-epoetin beta IV - Reported seizure

Methoxy polyethylene glycol-epoetin beta IV - Reported fever

Methoxy polyethylene glycol-epoetin beta IV - Bronchitis

Methoxy polyethylene glycol-epoetin beta IV - Reported cough

Use acceptable. No dose adjustment required.

The limited available data (case and post-marketing reports) in pregnant women are insufficient to identify major birth defects, miscarriage, or maternal/fetal adverse effects.
Pregnancy associated adverse outcomes from CKD include hypertension, pre-eclampsia, miscarriage, premature birth, low birth weight, polyhydramnios, and intrauterine growth restriction.
In animal lactation and pregnancy studies, offspring were adversely affected at doses 17 times the maximum recommended human dose.
The manufacturer makes no recommendation regarding use during pregnancy.

Assessment of erythropoietin for treatment of anemia in chronic kidney failure- ESRD patients.

Anemia and erythropoietin treatment in chronic kidney diseases.

Methoxy polyethylene glycol-epoetin beta

Table of contents